Background and Objectives. The new Abl tyrosine kinase inhibitor imatinib (imatinib mesylate, STI571) is very effective in the treatment of patients with chronic myeloid leukemia (CML). It induces complete hematologic control in >90% of patients with CML in chronic phase and preliminary data suggest that the incidence of complete cytogenetic remission may exceed 60% in previously untreated patients, though its capacity to prolong life in comparison with other agents has not yet been clearly established. It is also active in the management of patients in advanced phases of CML. Information sources. We present here provisional indications for the use of imatinib in CML patients and give details of the dosage regimens we have used and sideeffects we have encountered. State of the Art and Perspectives. It is likely that the optimal usage of this important new agent will become better defined as more experience is gained.
|Number of pages||10|
|Publication status||Published - Sep 1 2002|
ASJC Scopus subject areas